Elevated proportion of small, dense low-density lipoprotein particles and lower adiponectin blood levels predict early structural valve degeneration of bioprostheses

Cardiology

Volumn 121, Issue 1, 2012, Pages 20-26

  Shetty, Rahul ^a   Girerd, Nicolas ^b   Côté, Nancy ^a   Arsenault, Benoit ^b   Després, Jean Pierre ^b   Pibarot, Philippe ^b   Mathieu, Patrick ^a,b  

^a UNIVERSITÉ LAVAL   (Canada)

^b LAVAL UNIVERSITY   (Canada)

Author keywords

Adiponectin; Bioprostheses; Lipid profile; Small dense low density lipoprotein; Structural valve degeneration

Indexed keywords

ADIPONECTIN; LOW DENSITY LIPOPROTEIN;

ADULT; ARTICLE; ATHEROSCLEROSIS; CONTROLLED STUDY; ECHOCARDIOGRAPHY; FEMALE; HEART HEMODYNAMICS; HEART VALVE BIOPROSTHESIS; HEART VALVE REGURGITATION; HUMAN; HYPERTENSION; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; STENOSIS; STRUCTURAL VALVE DEGENERATION; TRIACYLGLYCEROL BLOOD LEVEL; VALVULAR HEART DISEASE;

ADIPONECTIN; AGED; AORTIC VALVE; AORTIC VALVE INSUFFICIENCY; AORTIC VALVE STENOSIS; BIOLOGICAL MARKERS; BIOPROSTHESIS; ECHOCARDIOGRAPHY, DOPPLER; FEMALE; FOLLOW-UP STUDIES; HEART VALVE PROSTHESIS; HUMANS; LIPOPROTEINS, LDL; MALE; MIDDLE AGED; PARTICLE SIZE; PROSTHESIS FAILURE;

EID: 84857471411     PISSN: 00086312     EISSN: 14219751     Source Type: Journal    
DOI: 10.1159/000336170     Document Type: Article

References (26)

1. Schoen FJ, Levy RJ: Founder's Award, 25th Annual Meeting of the Society for Biomaterials, perspectives. Providence, RI, April 28-May 2, 1999. Tissue heart valves: Current challenges and future research perspectives. J Biomed Mater Res 1999; 47: 439-465. (Pubitemid 29468549)
2. Manji RA, Zhu LF, Nijjar NK, Rayner DC, Korbutt GS, Churchill TA, Rajotte RV, Koshal A, Ross DB: Glutaraldehyde-fixed bioprosthetic heart valve conduits calcify and fail from xenograft rejection. Circulation 2006; 114: 318-327. (Pubitemid 44297098)
3. Nollert G, Miksch J, Kreuzer E, Reichart B: Risk factors for atherosclerosis and the degeneration of pericardial valves after aortic valve replacement. J Thorac Cardiovasc Surg 2003; 126: 965-968. (Pubitemid 37305676)
4. Farivar RS, Cohn LH: Hypercholesterolemia is a risk factor for bioprosthetic valve calcification and explantation. J Thorac Cardiovasc Surg 2003; 126: 969-975.
5. Briand M, Pibarot P, Despres JP, Voisine P, Dumesnil JG, Dagenais F, Mathieu P: Metabolic syndrome is associated with faster degeneration of bioprosthetic valves. Circulation 2006; 114:I512-I517. (Pubitemid 44297200)
6. Shetty R, Pibarot P, Audet A, Janvier R, Dagenais F, Perron J, Couture C, Voisine P, Despres JP, Mathieu P: Lipid-mediated inflammation and degeneration of bioprosthetic heart valves. Eur J Clin Invest 2009; 39: 471-480.
7. Antonini-Canterin F, Zuppiroli A, Popescu BA, Granata G, Cervesato E, Piazza R, PaVan D, Nicolosi GL: Effect of statins on the progression of bioprosthetic aortic valve degeneration. Am J Cardiol 2003; 92: 1479-1482. (Pubitemid 37532579)
8. Krauss RM, Burke DJ: Identification of multiple subclasses of plasma low density lipoproteins in normal humans. J Lipid Res 1982; 23: 97-104. (Pubitemid 12112617)
9. St-Pierre AC, Ruel IL, Cantin B, Dagenais GR, Bernard PM, Despres JP, Lamarche B: Comparison of various electrophoretic characteristics of LDL particles and their relationship to the risk of ischemic heart disease. Circulation 2001; 104: 2295-2299. (Pubitemid 33049511)
10. Rainwater DL, Mitchell BD, Comuzzie AG, Haffner SM: Relationship of low-density lipoprotein particle size and measures of adiposity. Int J Obes Relat Metab Disord 1999; 23: 180-189. (Pubitemid 29057514)
11. Cheng ML, Kammerer CM, Lowe WF, Dyke B, VandeBerg JL: Method for quantitating cholesterol in subfractions of serum lipoproteins separated by gradient gel electrophoresis. Biochem Genet 1988; 26: 657-681. (Pubitemid 19051291)
12. Mohty D, Pibarot P, Despres JP, Cote C, Arsenault B, Cartier A, Cosnay P, Couture C, Mathieu P: Association between plasma LDL particle size, valvular accumulation of oxidized LDL, and inflammation in patients with aortic stenosis. Arterioscler Thromb Vasc Biol 2008; 28: 187-193
13. Arsenault BJ, Lemieux I, Despres JP, Wareham NJ, Luben R, Kastelein JJ, Khaw KT, Boekholdt SM: Cholesterol levels in small LDL particles predict the risk of coronary heart disease in the EPIC-Norfolk prospective population study. Eur Heart J 2007; 28: 2770-2777. (Pubitemid 350135531)
14. Moon JY, Kwon HM, Kwon SW, Yoon SJ, Kim JS, Lee SJ, Park JK, Rhee JH, Yoon YW, Hong BK, Rim SJ, Kim HS: Lipoprotein(a) and LDL particle size are related to the severity of coronary artery disease. Cardiology 2007; 108: 282-289. (Pubitemid 350126472)
15. Kwon SW, Yoon SJ, Kang TS, Kwon HM, Kim JH, Rhee J, Lee SJ, Park JK, Lim JY, Yoon YW, Hong BK: Significance of small dense lowdensity lipoprotein as a risk factor for coronary artery disease and acute coronary syndrome. Yonsei Med J 2006; 47: 405-414. (Pubitemid 43984170)
16. Despres JP, Arsenault BJ, Cote M, Cartier A, Lemieux I: Abdominal obesity: The cholesterol of the 21st century? Can J Cardiol 2008; 24(suppl D):7D-12D.
17. Austin MA, King MC, Vranizan KM, Krauss RM: Atherogenic lipoprotein phenotype. A proposed genetic marker for coronary heart disease risk. Circulation 1990; 82: 495-506. (Pubitemid 20257828)
18. Watson TD, Caslake MJ, Freeman DJ, Griffin BA, Hinnie J, Packard CJ, Shepherd J: Determinants of LDL subfraction distribution and concentrations in young normolipidemic subjects. Arterioscler Thromb 1994; 14: 902-910.
19. Berg AH, Combs TP, Du X, Brownlee M, Scherer PE: The adipocyte-secreted protein Acrp30 enhances hepatic insulin action. Nat Med 2001; 7: 947-953. (Pubitemid 32756433)
20. Masaki T, Chiba S, Yasuda T, Tsubone T, Kakuma T, Shimomura I, Funahashi T, Matsuzawa Y, Yoshimatsu H: Peripheral, but not central, administration of adiponectin reduces visceral adiposity and upregulates the expression of uncoupling protein in agouti yellow (Ay/a) obese mice. Diabetes 2003; 52: 2266-2273. (Pubitemid 37059496)
21. Okamoto Y, Kihara S, Ouchi N, Nishida M, Arita Y, Kumada M, Ohashi K, Sakai N, Shimomura I, Kobayashi H, Terasaka N, Inaba T, Funahashi T, Matsuzawa Y: Adiponectin reduces atherosclerosis in apolipoprotein E-deficient mice. Circulation 2002; 106: 2767-2770. (Pubitemid 35396973)
22. Tian L, Luo N, Klein RL, Chung BH, Garvey WT, Fu Y: Adiponectin reduces lipid accumulation in macrophage foam cells. Atherosclerosis 2009; 202: 152-161.
23. Maeda N, Takahashi M, Funahashi T, Kihara S, Nishizawa H, Kishida K, Nagaretani H, Matsuda M, Komuro R, Ouchi N, Kuriyama H, Hotta K, Nakamura T, Shimomura I, Matsuzawa Y: PPARgamma ligands increase expression and plasma concentrations of adiponectin, an adipose-derived protein. Diabetes 2001; 50: 2094-2099. (Pubitemid 33643677)
24. Combs TP, Wagner JA, Berger J, Doebber T, Wang WJ, Zhang BB, Tanen M, Berg AH, O'Rahilly S, Savage DB, Chatterjee K, Weiss S, Larson PJ, Gottesdiener KM, Gertz BJ, Charron MJ, Scherer PE, Moller DE: Induction of adipocyte complement-related protein of 30 kilodaltons by PPARgamma agonists: A potential mechanism of insulin sensitization. Endocrinology 2002; 143: 998-1007. (Pubitemid 34164048)
25. Gaw A, Packard CJ, Caslake MJ, Griffin BA, Lindsay GM, Thomson J, Vallance BD, Wosornu D, Shepherd J: Effects of ciprofibrate on LDL metabolism in man. Atherosclerosis 1994; 108: 137-148. (Pubitemid 24265886)
26. Guerin M, Bruckert E, Dolphin PJ, Turpin G, Chapman MJ: Fenofibrate reduces plasma cholesteryl ester transfer from HDL to VLDL and normalizes the atherogenic, dense LDL profile in combined hyperlipidemia. Arterioscler Thromb Vasc Biol 1996; 16: 763-772. (Pubitemid 26179365)